Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 67, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2022.102304
Keywords
-
Categories
Ask authors/readers for more resources
Fibroblast-like synoviocytes (FLS) play an important role in rheumatoid arthritis (RA), but in RA, fibroblasts become a key driver of synovial inflammation and joint damage. There has been recent interest in targeting FLS for RA treatment and the effects of FLS-targeted drugs are discussed.
Fibroblast-like synoviocytes (FLS) are mesenchymal-derived cells that play an important role in the physiology of the synovium by producing certain components of the synovial fluid and articular cartilage. In rheumatoid arthritis (RA), however, fibroblasts become a key driver of synovial inflammation and joint damage. Because of this, there has been recent interest in FLS as a therapeutic target in RA to avoid side effects such as systemic immune suppression associated with many existing RA treatments. In this review, we describe how approved treatments for RA affect FLS signaling and function and discuss the effects of investigational FLS-targeted drugs for RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available